Klinge Biopharma GmbH

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. B+L Bolsters Ophthalmology With Acquis

Teva has bolstered its biosimilars business with a pair of alliances that will give the Israeli off-patent giant rights to Samsung Bioepis’ Soliris (eculizumab) rival in the US and Formycon’s version

The European Medicines Agency has recommended that pan-EU marketing authorization should be granted to eight new drugs, including Gohibic (vilobelimab) and Augtyro (repotrectinib), from InflaRx and Br

Klinge Biopharma , Formycon ’s exclusive license holder for its aflibercept biosimilar, has chosen MS Pharma as its commercialization partner in the Middle East and North Africa region. MS Pharma wil